FY2025 EPS Estimates for Longeveron Reduced by Roth Capital

Longeveron Inc. (NASDAQ:LGVN) – Investment analysts at Roth Capital reduced their FY2025 earnings estimates for Longeveron in a research report issued to clients and investors on Tuesday, November 4th. Roth Capital analyst B. Pachaiyappan now expects that the company will earn ($1.48) per share for the year, down from their prior estimate of ($1.18). Roth Capital currently has a “Buy” rating and a $3.00 price objective on the stock. The consensus estimate for Longeveron’s current full-year earnings is ($3.69) per share. Roth Capital also issued estimates for Longeveron’s Q4 2025 earnings at ($0.41) EPS, Q1 2026 earnings at ($0.24) EPS, Q2 2026 earnings at ($0.25) EPS, Q3 2026 earnings at ($0.24) EPS, Q4 2026 earnings at ($0.25) EPS and FY2026 earnings at ($0.98) EPS.

Longeveron (NASDAQ:LGVN) last released its quarterly earnings data on Tuesday, November 4th. The company reported ($0.39) earnings per share for the quarter, missing the consensus estimate of ($0.26) by ($0.13). Longeveron had a negative return on equity of 138.44% and a negative net margin of 1,485.25%.The business had revenue of $0.14 million for the quarter, compared to analyst estimates of $0.29 million.

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Longeveron in a research note on Wednesday, October 8th. Three analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $7.67.

Longeveron Stock Up 1.0%

Shares of LGVN stock opened at $0.77 on Friday. The company has a market cap of $16.22 million, a P/E ratio of -0.76 and a beta of 0.16. The business has a 50 day moving average of $0.81 and a two-hundred day moving average of $1.15. Longeveron has a 52 week low of $0.63 and a 52 week high of $2.31.

Institutional Trading of Longeveron

An institutional investor recently bought a new position in Longeveron stock. XTX Topco Ltd bought a new position in shares of Longeveron Inc. (NASDAQ:LGVN) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 48,003 shares of the company’s stock, valued at approximately $62,000. XTX Topco Ltd owned approximately 0.32% of Longeveron as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors own 10.01% of the company’s stock.

Longeveron Company Profile

Longeveron Inc, a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States and Japan. The company’s lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors.